Manage episode 288102976 series 2115198
Selecta Biosciences is developing a platform to promote immuno-tolerance. Many treatment regiments have unwanted immune responses that can reduce the therapy's efficacy or cause immunity against the vector in a gene therapy. They are also seeking indications in autoimmune diseases. If successful, SELB's platform would see massive adoption. They recently had negative data in a Phase 2 trial of Gout, but because upcoming catalysts are for other programs, I see an opportunity.
I also discuss new data from Eli Lilly, Annovis and Marker Therapeutics.
If you want to check out our sponsor, go to Gallant.com and use promo code: BIO to save when you enroll your pet for stem cell banking.
If you want to help out the show (or join the discord), become a patron at: https://www.patreon.com/breakingbiotech Follow me on twitter @matthewlepoire Send me an email email@example.com www.breakingbiotech.com
Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech